These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35488725)

  • 21. TAFRO Syndrome: A Disease Requiring Immediate Medical Attention.
    Masaki Y; Ueda Y; Yanagisawa H; Arita K; Sakai T; Yamada K; Mizuta S; Fukushima T; Takai K; Aoki S; Kawabata H
    Intern Med; 2023 Jan; 62(1):27-32. PubMed ID: 35598998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International definition of iMCD-TAFRO: future perspectives.
    Nishimura Y; Nishimura MF; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TAFRO Syndrome.
    Igawa T; Sato Y
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunology and targeted therapy in Castleman disease.
    Tsunoda S; Harada T; Kikushige Y; Kishimoto T; Yoshizaki K
    Expert Rev Clin Immunol; 2024 Sep; 20(9):1101-1112. PubMed ID: 38785062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
    Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peculiar hyper vascular manifestations in idiopathic multicentric castleman disease without tafro syndrome: a case report.
    Jilani RK; Saleem MR; Akhtar S; Jawad W
    Ann Hematol; 2024 Oct; ():. PubMed ID: 39400742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
    Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
    Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
    Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
    Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient.
    Miatech JL; Patel NR; Latuso NQ; Ellipeddi PK
    Cureus; 2019 Jun; 11(6):e4946. PubMed ID: 31453020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
    Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.
    Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y
    Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.
    Zhou Q; Zhang Y; Zhou G; Zhu J
    BMC Nephrol; 2020 Nov; 21(1):499. PubMed ID: 33225930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.
    Shirakashi M; Nishida Y; Nakashima R; Fujimoto M; Hiwa R; Tsuji H; Kitagori K; Akizuki S; Morinobu A; Yoshifuji H
    Sci Rep; 2024 Feb; 14(1):2889. PubMed ID: 38311632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report.
    Shiina T; Yamamoto EK; Yamada H; Sendo S; Kanzawa M; Saegusa J
    Mod Rheumatol Case Rep; 2024 Aug; ():. PubMed ID: 39177383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
    Bustamante MS; Pierson SK; Ren Y; Bagg A; Brandstadter JD; Srkalovic G; Mango N; Alapat D; Lechowicz MJ; Li H; Van Rhee F; Lim MS; Fajgenbaum DC
    Haematologica; 2024 Jul; 109(7):2196-2206. PubMed ID: 38205523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.
    Srkalovic G; Nijim S; Srkalovic MB; Fajgenbaum D
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tacrolimus Treatment for TAFRO Syndrome.
    Shirai T; Ichikawa S; Saegusa J
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38791031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
    Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y
    Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
    Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
    Front Immunol; 2019; 10():1489. PubMed ID: 31316523
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.